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Among 1276 primary breast carcinoma in situ (BCIS) patients diagnosed in 1972–2002 in the Southern Netherlands, 11% developed
a second cancer. Breast carcinoma in situ patients exhibited a two-fold increased risk of second cancer (standardised incidence ratios
(SIR): 2.1, 95% confidence interval (CI): 1.7–2.5). The risk was highest for a second breast cancer (SIR: 3.4, 95% CI: 2.6–4.3; AER: 66
patients per 10 000 per year) followed by skin cancer (SIR: 1.7, 95% CI: 1.1–2.6; AER: 17 patients per 10 000 per year). The increased
risk of second breast cancer was similar for the ipsilateral (SIR: 1.9, 95% CI: 1.3–2.7) and contralateral (SIR: 2.0, 95% CI: 1.4–2.8)
breast. Risk of second cancer was independent of age at diagnosis, type of initial therapy, histologic type of BCIS and period of
diagnosis. Standardised incidence ratios of second cancer after BCIS (SIR: 2.3, 95% CI: 1.8–2.8) resembled that after invasive breast
cancer (SIR: 2.2, 95% CI: 2.1–2.4). Surveillance should be directed towards second (ipsi- and contra-lateral) breast cancer.
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Diagnosis of ductal breast carcinoma in situ has increased in the
Netherlands, partly as a consequence of screening (Fracheboud
et al, 2004), from 0.3 per 100 000 in 1975 to 13.4 per 100 000 in 1997
(Voogd et al, 2000). Women with previous breast cancer are
known to carry a two-fold increased risk of second cancer in
comparison to the general population (Rubino et al, 2003;
Soerjomataram et al, 2005a). Studies assessing the risk of second
cancer following the diagnosis of BCIS (breast carcinoma in situ)
are however scarce or only focused on the risk of second breast
cancer (Habel et al, 1997; Warnberg et al, 2000; Claus et al, 2003;
Levi et al, 2005; Rawal et al, 2005).
An increased risk of 2.0–7.2 for breast cancer following the
diagnosis of BCIS has been reported (Franceschi et al, 1998; Rawal
et al, 2005), the probability that a breast cancer will develop in
BCIS patients being 26% after 20 years of follow-up (Levi et al,
2005). This is as high as the risk of second breast cancer found for
patients with malignant breast carcinoma (Chen et al, 2001).
Excess risk of second breast cancer is not explained by treatment
choice (i.e. radiotherapy) for BCIS (Claus et al, 2003), suggesting a
shared aetiology (hereditary or lifestyle) for both first and second
cancer. In addition to second breast cancer, other cancers were
diagnosed in 17% of DCIS and 3.2% of lobular carcinoma in situ
(LCIS) patients (Ward et al, 1992). However, no previous studies
assessed the risks of different types of second cancer in BCIS
patients.
The aim of the study is to assess the risk pattern for second
cancer after diagnosis of BCIS and to compare it with that found
for malignant breast carcinoma, thereby examining the impact of
age, breast cancer screening policy at the time of primary BCIS
diagnosis and treatment for various subtypes of BCIS.
MATERIALS AND METHODS
Data collection
Data were obtained from the population-based ECR (Eindhoven
Cancer Registry) in the Southern Netherlands, covering 2.4 million
inhabitants in 2004. The cancer registry is notified of newly
diagnosed cases by the pathology departments in the region. In
addition, lists of all hospitalised cancer patients were obtained.
Active follow-up of vital status was conducted through the Central
Bureau for Genealogy that receives data from municipal popula-
tion registries. In the ECR, any new tumour, not classified as a
recurrence or direct extension of a previously known tumour, is
recorded as a new primary tumour. This registry also records
incidence data on first basal cell carcinoma (BCC) of the skin. A
detailed description of the data collection has been presented
elsewhere (Soerjomataram et al, 2005a).
Study population
We identified 1402 women older than 25 years diagnosed with in
situ breast cancer (ICD-O behaviour code/2) from 1 January 1972
through 31 December 2002. Among patients eligible for the study,
those with less than 1-year follow-up time (n¼ 174) and those with
unknown morphological code (n¼ 5) were excluded. End of
follow-up was 31 December 2003, date of death, date of last follow-
up or date of second cancer diagnosis, whichever occurred first.
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Thus, 1223 women remained for analysis, 143 of whom (11.2%)
developed a second cancer, 170 (13.3%) died and 2 (0.2%) were
lost to follow-up. The maximum follow-up time was of 32 years.
Statistical methods
We calculated standardised incidence ratios (SIRs) to measure the
relative risk of developing second tumours by comparing the
incidence of second cancer among patients with a diagnosis of
BCIS to the incidence of similar cancer in the general population.
We adjusted for age (in 5-year categories) and calendar year of
BCIS diagnosis. The 95% confidence intervals (95% CI) were
calculated using exact Poisson probability (Breslow and Day,
1987). We also calculated the absolute excess risk (AER) examining
the excess incidence of second cancers per 10 000 patients in each
year (van Leeuwen and Travis, 2005). Furthermore, the cumulative
risk of developing second cancer, which is the proportion of
patients alive at time t who can be expected to develop a second
cancer, was calculated using the life table method (Cutler and
Ederer, 1958).
The following categorisation of BCIS histological type was made;
LCIS (ICD-O 8520/2) and DCIS including Paget’s disease (ICD-O
8500/2, 8010/2, 8050/2, 8140/2, 8201/2, 8230/1, 8501/2, 8503/2,
8504/2, 8507/2, 8521/1, 8523/2, 8540/2) (Vereniging van Integrale
Kankercentra, 2005). Year 1993 was considered the starting point
of breast cancer screening, which was fully implemented in 1996
(Fracheboud et al, 1998, 2004). Calculation of risk for the
ipsilateral and contralateral second breast cancer was performed
using only patients with information on laterality of first BCIS and
second breast cancer (excluded for this analysis n¼ 52).
Standardised incidence ratios for selected cancers after malig-
nant breast cancer were obtained from a previous study performed
in ECR (Soerjomataram et al, 2005a) and compared with that of
BCIS in the current study. In the earlier study, we estimated the
risk of subsequent cancers in 9919 women diagnosed with
malignant breast cancers in 1972–2000 followed until 2001. To
allow comparison, we added second nonmelanotic skin cancer
cases (BCC: 192 and squamous cell carcinoma: 42) for the analysis
of second skin cancer. We used a similar method to calculate
SIRs and 95% confidence intervals as explained before. A
detailed description of this study has been described elsewhere
(Soerjomataram et al, 2005a).
All statistical analyses were performed using SPSS 11.5 for
Windows (Statistical Products and Service Solution, Inc., Chicago,
IL, USA).
RESULTS
The mean follow-up time for the cohort was 6.3 years. A large
proportion of BCIS patients was older than 50 years and was
diagnosed with DCIS (95%) in 1993–2002 (Table 1).
Table 2 shows the SIRs and AERs for second breast and other
cancers. We found an increased risk of second breast cancer (SIR:
2.1, 95% CI: 1.7–2.5) and other non-breast cancers (SIR: 1.4, 95%
CI: 1.1–1.9). An excess of 66 patients with second breast cancer for
every 10 000 BCIS patients per year was observed. An increased
risk of second breast cancer was found for both the ipsilateral (SIR:
1.9, 95% CI: 1.3– 2.7) and contralateral breast (SIR: 2.0, 95% CI:
1.4–2.8). Almost a two-fold elevated risk of skin cancer (SIR: 1.7,
95% CI: 1.1–2.5) was found.
A three- to four-fold increased risk of second breast cancer was
found during the first 10 years of follow-up (Table 3), which was
relatively higher than the SIR for the last follow-up period (X10
years). As for the risk of second non-breast cancer, we observed
similar SIRs across all follow-up periods.
Increased risks of second breast or other cancers were not
influenced by age at BCIS diagnosis, type of initial therapy,
histological type of BCIS and time of BCIS diagnosis (Table 4).
Ipsi- and contra-lateral invasive breast cancer risks were slightly
higher for BCIS patients who received radiotherapy (SIR: 2.1, 95%
CI: 1.0–4.0 and SIR: 2.4, 95% CI: 1.2–4.3, respectively), compared
Table 1 Characteristics at diagnosis of BCIS (breast carcinoma in situ)a
Subsequent cancer
No. (%) Yes (%) Total (%)
Age at BCIS diagnosis
p49 years 288 (26) 30 (27) 318 (26)
X50 years 822 (74) 83 (73) 905 (74)
Initial treatment
No radiotherapy 765 (69) 68 (60) 833 (68)
With radiotherapy 345 (31) 45 (40) 390 (32)
Follow-up
1–4 years 549 (49) 64 (57) 613 (50)
5–9 years 396 (36) 34 (30) 430 (35)
X10 years 165 (15) 15 (13) 180 (15)
Subtype of initial cancer
DCISb 1052 (95) 105 (93) 1157 (95)
LCISc 58 (5) 8 (7) 66 (5)
Time of diagnosisd
1972–1992 165 (15) 41 (36) 206 (17)
1993–2002 945 (85) 72 (64) 1017 (83)
Total 1110 113 1223 (100)
aMean age at BCIS diagnosis¼ 57.1 years; Mean follow-up time¼ 6.3 years bDCIS:
ductal carcinoma in situ. cLCIS: lobular carcinoma in situ. dBreast cancer screening in
southern Netherlands began to have impact in 1993 (Fracheboud et al, 2004).
Table 2 Standardised incidence ratio (SIR) and absolute excess risk
(AER) for all second cancers diagnosed in 1972–2003 following BCIS
(breast carcinoma in situ) in southern Netherlands
Relative and absolute risksa
Site of second cancer Observed Expected SIR 95% CI AER
All sites 113 54.4 2.1b 1.7–2.5 90
All sites excluding breastc 52 36.2 1.4b 1.1–1.9 24
Digestive tractd 11 10.4 1.1 0.5–1.9 1
Stomach 3 1.6 1.8 0.4–5.3 2
Colon 6 5.2 1.2 0.4–2.5 1
Lung 5 3.5 1.4 0.5–3.3 2
Skine 27 15.8 1.7b 1.1–2.5 17
Melanoma 4 1.4 3.0 0.8–7.6 4
Basal cell carcinoma 22 12.8 1.7b 1.1–2.6 14
Breast 61 18.1 3.4b 2.6–4.3 66
Ipsilateralf 29 15.5 1.9b 1.3–2.7 24
Contralateralf 31 15.5 2.0b 1.4–2.8 28
Urogenital tractg 4 7.1 0.6 0.2–1.4 5
Ovary 2 2.5 0.8 0.1–2.8 1
Lymphoma and multiple myeloma 2 2.5 0.8 0.1–2.9 1
aExcluding patients with less than 1-year follow-up. b95% confidence interval excludes
1. cThree observed are primary cancers of unknown origin. dAlso includes pancreas
[1] and rectum [1]. eAlso includes squamous cell carcinoma of the skin [1] fOnly
includes patients with known laterality of BCIS and second breast cancer. gAlso
includes corpus uteri [1] and bladder [1].
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to patients who did not receive radiotherapy (SIR: 1.7, 95% CI:
1.1–2.8 and SIR: 1.8, 95% CI: 1.1– 2.8). The cumulative 10-year
risk of developing any second cancer was 17% (75%), whereas the
15-year corresponding risk was 21% (78%) (Figure 1).
Figure 2 compares the SIRs for second cancer after BCIS with
those after invasive breast cancer for selected malignancies. The
SIRs for second cancer of the lung, colon, skin and breast after
BCIS were similar to those after invasive breast cancer. The risk
pattern of second cancer at all sites after BCIS (SIR: 2.3, 95% CI:
1.8–2.8) was similar to that of second cancer after invasive breast
cancer (SIR: 2.2, 95% CI: 2.1– 2.4).
DISCUSSION
Women previously diagnosed with in situ breast carcinoma had an
increased risk of second cancer, in particular second breast and
skin cancer. An excess of 90 second cancers per 10 000 BCIS
patients was found. Similar to previous studies (Franceschi et al,
1998), we observed a 21% increased risk for a second cancer after
15 years of survival.
Some limitations of our study should be considered. Firstly, as
most women were diagnosed after 1993, the majority had less than
10 years of follow-up. Furthermore, the absolute numbers of our
study is relatively small. Thus, we may not have estimated correctly
the long-term risk of less common cancers such as ovarian cancer,
which exhibits an increased risk among long-term survivors
of invasive breast cancer (Soerjomataram et al, 2005b). Secondly,
increased medical surveillance of women with a diagnosis of BCIS
may have increased detection of second cancers (van Leeuwen and
Travis, 2005). In our cohort, 60% (30 patients) were diagnosed
with second cancer within the first year after BCIS diagnosis.
Therefore, we excluded patients with less than 1-year of follow-up
and those with a second carcinoma in situ. Thirdly, AER in this
article should be interpreted with caution because BCIS accounts
for only approximately 13% of all breast cancer diagnoses
(Fracheboud et al, 2004). Thus, given the same AER, the absolute
number of second cancers after BCIS will be considerably smaller
than that after invasive breast cancer at the population level.
Lastly, no individual data were available on risk factors for cancer
(Soerjomataram et al, 2005b). Hence, the contribution of these
factors to the risk of second cancer could not be assessed.
Risk pattern
After the diagnosis of BCIS, there was an increased risk of second
breast and skin cancer. The question is whether second
malignancies share a common aetiology with the first cancer or
whether they are associated with treatment for the first cancer
(van Leeuwen and Travis, 2005). It is likely that factors including
reproductive characteristics, lifestyle and genetic predisposition
such as BRCA2 play a more important role in the excess risk of
both second breast and skin cancer after BCIS (Arver et al, 2000;
Goggins et al, 2004). We did not find an increased risk of second
ovarian cancer among BCIS patients as in patients with malignant
breast cancer. However, most patients in this study had less than
10 years of follow-up and the risk of ovarian cancer after breast
cancer was highest after more than 15 years of follow-up
(Soerjomataram et al, 2005b).
Table 3 Standardised incidence ratio (SIR) and absolute excess risk (AER) for second breast cancer and second other cancers after BCIS (breast
carcinoma in situ), according to follow-up time
Second breast cancer Other second cancers
Period of follow-up PYRa Obsb Expc SIR AER Obsb Expc SIR AER
1–4 years 3596 33 9.7 3.4d 65 31 18.9 1.6d 34
5–9 years 1815 22 5.0 4.4d 94 12 10.1 1.2 11
X10 years 1127 6 3.3 1.8 24 9 7.4 1.2 14
aPYR: person-years. bObs: observed numbers of second primary cancers. cExp: expected numbers of second primary cancers. d95% confidence interval excludes 1.
Table 4 Standardised incidence ratio (SIR) and absolute excess risk (AER) for all second cancers diagnosed 1972–2003 following BCIS (breast carcinoma
in situ) in southern Netherlands, according to women’s characteristics at the time of BCIS diagnosis
Second breast cancer Second other cancers
Characteristic PYRa Obsb Expc SIR AER Obsb Expc SIR AER
Age at diagnosis
p49 years 2334 20 4.9 4.0d 65 10 6.6 1.5 15
X50 years 4204 41 13.1 3.1d 66 42 29.8 1.4d 29
Treatment
No Radiotherapy 4474 39 12.4 3.1d 59 29 25.2 1.1 8
With Radiotherapy 2064 22 5.6 3.9d 79 23 11.1 2.1e 57
Subtype of initial cancer
DCIS 6106 58 16.8 3.4d 67 47 34.3 1.4d 21
LCIS 432 3 1.2 2.5 42 5 2.1 2.4 67
Time of diagnosise
1972–1992 2708 24 7.0 3.4d 63 17 14.4 1.2 9
1993–2002 3830 37 11.0 3.4d 68 35 21.9 1.6d 34
aPYR: person-years. bObs: observed numbers of second primary cancers. cExp: expected numbers of second primary cancers. d95% confidence interval excludes 1. eBreast cancer
screening in southern Netherlands began to have impact in 1993 (Fracheboud et al, 2004).
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Determinants
Age Age at the time of BCIS diagnosis did not seem to influence
the risk for second cancer, although we observed a slightly higher
risk of second breast cancer among women diagnosed with BCIS
before age 50. A higher risk of second breast cancer has been found
among in situ and malignant breast cancer patients diagnosed
before the age of 50 years (Rawal et al, 2005; Soerjomataram et al,
2005b). This is partly due to genetic predisposition, which usually
becomes manifest at a relatively young age.
Treatment The risk for second (ipsi- and contra-lateral) breast
and other cancers was slightly higher among BCIS patients who
received radiotherapy. Radiation after breast-conserving treatment
reduces recurrences in the ipsilateral breast (Fisher et al, 1993;
Julien et al, 2000), but its effect on the risk of new (ipsi- or contra-
lateral) breast cancer is less conclusive (Warnberg et al, 2001;
Claus et al, 2003). We found only a slightly increased risk of
second breast cancer after radiation that was not significantly
different from that of patients without radiotherapy. Thus, the
benefit of radiation after surgery for the overall survival of DCIS
patients seems to outweigh the increased risk of second breast
cancer (Fisher et al, 1993).
Screening The risk of second cancer after BCIS remained elevated
and of a similar magnitude after implementation of the national
screening policy in the Netherlands. In Sweden, the risk of second
breast cancer increased at the beginning of the screening period
and only decreased after long implementation of national screen-
ing (Rawal et al, 2005). Thus, in the coming decades, we might
observe a decrease in the risk of second cancer after BCIS.
Comparison with invasive breast cancer cohort
The pattern of second cancer after BCIS seems to be similar to that
after malignant breast cancer. Cancers of the colorectum, ovarium,
lung and skin were some of the most common cancers in women
previously diagnosed with an invasive breast cancer (Soerjomatar-
am et al, 2005a). In the USA, colorectal, cervical and endometrial
cancer were reported as the most prevalent cancers among BCIS
patients (Ward et al, 1992). Thus, we could probably expect an
increased incidence of second cancers resembling that of
malignant breast cancer within a larger study population and a
longer follow-up of BCIS cases.
In conclusion, we found increased relative and absolute risks of
second cancer after BCIS diagnosis, similar to that after invasive
breast cancer. Monitoring for these breast cancers should therefore
be conducted in both the ipsilateral and the contralateral breast.
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